Vonoprazan for gastroesophageal reflux disease: study protocol for a pragmatic, crossover-cluster, randomized controlled trail

INTERVENTION: A regimen:vonoprazan 20mg p.o. before or after breakfast;B regimen:vonoprazan 20mg p.o. before or after dinner;C regimen:vonoprazan 20mg p.o. before or after breakfast, and before or after dinner; CONDITION: gastroesophageal reflu Xdisease PRIMARY OUTCOME: The rate of symptom relief;The healing rate of esophageal mucosa; SECONDARY OUTCOME: The score of quality of life; INCLUSION CRITERIA: 1)=18 years old 2)Patients having completed upper gastrointestinal endoscopy in the past one year 3)Patients with typical symptoms for at least one month and GERD‐Q=8; or patients with untypical symptoms for at least one month and erosive esophagitis grade B/C/D; 4)Adherence to the allocated regimens and the follow‐up procedure